26.7 C
New York
Sunday, July 3, 2022

Altamira Therapeutics Ltd. (CYTO) stock skyrocketed in the Current Market; here is why?

Altamira Therapeutics Ltd. (CYTO) stock gained significantly in the current market after announcing a peer-reviewed publication for its treatment of the delta variant. CYTO stock values at around $1.54, gaining more than 43.93% from the previous close. The stock closed at approximately $1.07 with a trading volume of about 822.46K shares.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Pharma Industry Overview Global and the US

Altamira Therapeutics Ltd. (CYTO) is a player in the pharmaceutical industry and has been focused on developing a treatment for covid-19 since its outbreak.

The Pharma sector was worth roughly $100.9 billion in 2020. In FY27, the global pharmaceutical industry is expected to expand 14.8% to $267.4. During COVID19, the pharmaceutical industry focused on viral vectors in the virotherapy and vaccine industries to develop effective vaccines and pharmaceutical therapeutics. Pharma has started post-vaccine efforts. These initiatives will benefit from the industry’s experiences during the COVID19 outbreak.

North America had 46% of the global pharmaceutical market in FY20. The Asia-Pacific medications market accounted for 26% of the worldwide total.

The pharmaceutical industry’s manufacturing sector is expected to grow even faster. Manufacturers of pharmaceuticals worldwide benefit from increased attention to elderly and pediatric patients, rising cardiovascular and diabetes rates, and an increase in persons seeking home healthcare. The global pharmaceutical manufacturing business is expected to grow at a CAGR of 12.8% from FY21 to FY30.

Altamira Therapeutics shares peer-reviewed publication

The company announced a peer-reviewed International Journal of Molecular Sciences (IJMS) paper. This publication confirms the Company’s excellent research results regarding the in vitro effectiveness and safety of its drug-free nasal spray, BentrioTM, against the SARS-CoV-2 Delta variant. Bento(TM) is effective and safe in vitro for the Delta Variant.

This treatment reduced the virus intensity in human nasal mucosa by 99 percent with the wild-type SARS-CoV-2 variation and more than 83 percent with the Delta variant over four days.

The virus titer decreased by roughly 12-fold within 24 hours and 3-fold on Day 4. In the second research, BentrioTM showed promise against the Omicron form.

Conclusion

It seems like the company has cracked a treatment for the delta variant. It has been a significant development in the company’s research since 2020. They must now be looking forward to getting approval from FDA.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

[class^="wpforms-"]
[class^="wpforms-"]